ASTX660
ASTX660 is a pharmaceutical drug with 6 clinical trials. Currently 2 active trials ongoing. Historical success rate of 50.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
50.0%
2 of 4 finished
50.0%
2 ended early
2
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
Clinical Trials (6)
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6